Association of poly( < em > rC < /em > )-binding protein-2 with sideroflexin-3 through TOM20 as an iron entry pathway to mitochondria
In conclusion, we discovered a novel pathway of iron entry into mitochondria from cytosol through PCBP2-TOM20-SFXN3 axis.PMID:38599240 | DOI:10.1080/10715762.2024.2340711 (Source: Free Radical Research)
Source: Free Radical Research - April 10, 2024 Category: Research Authors: Danyang Mi Izumi Yanatori Hao Zheng Yingyi Kong Tasuku Hirayama Shinya Toyokuni Source Type: research
Study of the effect of sFRP1 protein on molecules involved in the regulation of DNA methylation in CML cell line
AbstractWnt-signaling pathway plays a crucial role in the pathogenesis and progression of Chronic Myeloid Leukemia (CML).sFRP1 is involved in the suppression of the Wnt-signaling pathway and has been shown to be epigenetically silenced by promoter hypermethylation during CML progression. DNMT3A plays a crucial role in promoter hypermethylation and is responsible for establishing methylation patterns. We aimed to analyze the relationship between sFRP1 exp ression and DNMT3A, TET1, TET2 and TET3 proteins that are responsible for maintaining cellular methylation patterns; along with miRNAs miR144-3p and miR-767-5p that are...
Source: Medical Oncology - April 9, 2024 Category: Cancer & Oncology Source Type: research
Simultaneous blastic plasmacytoid dendritic cell neoplasm and myelofibrosis: A case report
Oncol Lett. 2024 Mar 22;27(5):220. doi: 10.3892/ol.2024.14354. eCollection 2024 May.ABSTRACTBlastic plasmacytoid dendritic cell neoplasm (BPDCN) is an extremely rare and aggressive tumor with an unknown pathogenesis. Myelofibrosis (MF) is a type of myeloproliferative neoplasm. MF can be secondary to several hematological malignancies, including chronic myeloid leukemia, myelodysplastic syndrome and hairy cell leukemia. In the present report, a rare case of BPDCN secondary to MF is described. A 70-year-old male patient developed a large purplish-red rash with recurrent symptoms. BPDCN was confirmed by immunohistochemistry o...
Source: Oncology Letters - April 8, 2024 Category: Cancer & Oncology Authors: Fuyi Luo Bingjie Li Jing Li Yan Li Source Type: research
Changes in chronic myeloid leukemia treatment modalities and outcomes after introduction of second-generation tyrosine kinase inhibitors as first-line therapy: a multi-institutional retrospective study by the CML Cooperative Study Group
This study investigated changes in treatment modalities and outcomes of chronic myeloid leukemia in the chronic phase (CP-CML) after the approval of second-generation tyrosine kinase inhibitors (2G-TKIs) for first-line therapy. Patients were grouped into those who underwent TKI therapy up to December 2010 (imatinib era group, n = 185) and after January 2011 (2G-TKI era group, n = 425). All patients in the imatinib era group were initially treated with imatinib, whereas patients in the 2G-TKI era group were mostly treated with dasatinib (55%) or nilotinib (36%). However, outcomes including progression-free survival, overall...
Source: International Journal of Hematology - April 8, 2024 Category: Hematology Authors: Noriyoshi Iriyama Eisaku Iwanaga Yuta Kimura Naoki Watanabe Maho Ishikawa Hitomi Nakayama Eriko Sato Takayuki Tabayashi Toru Mitsumori Tomoiku Takaku Tomonori Nakazato Michihide Tokuhira Hiroyuki Fujita Miki Ando Yoshihiro Hatta Tatsuya Kawaguchi Source Type: research
Changes in chronic myeloid leukemia treatment modalities and outcomes after introduction of second-generation tyrosine kinase inhibitors as first-line therapy: a multi-institutional retrospective study by the CML Cooperative Study Group
This study investigated changes in treatment modalities and outcomes of chronic myeloid leukemia in the chronic phase (CP-CML) after the approval of second-generation tyrosine kinase inhibitors (2G-TKIs) for first-line therapy. Patients were grouped into those who underwent TKI therapy up to December 2010 (imatinib era group, n = 185) and after January 2011 (2G-TKI era group, n = 425). All patients in the imatinib era group were initially treated with imatinib, whereas patients in the 2G-TKI era group were mostly treated with dasatinib (55%) or nilotinib (36%). However, outcomes including progression-free survival, overall...
Source: International Journal of Hematology - April 8, 2024 Category: Hematology Authors: Noriyoshi Iriyama Eisaku Iwanaga Yuta Kimura Naoki Watanabe Maho Ishikawa Hitomi Nakayama Eriko Sato Takayuki Tabayashi Toru Mitsumori Tomoiku Takaku Tomonori Nakazato Michihide Tokuhira Hiroyuki Fujita Miki Ando Yoshihiro Hatta Tatsuya Kawaguchi Source Type: research
Corrigendum: Comorbidities and outcomes of patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: a real-world, nationwide, retrospective study from Hungary
Pathol Oncol Res. 2024 Mar 21;30:1611758. doi: 10.3389/pore.2024.1611758. eCollection 2024.ABSTRACT[This corrects the article DOI: 10.3389/pore.2024.1611497.].PMID:38576767 | PMC:PMC10991778 | DOI:10.3389/pore.2024.1611758 (Source: Pathology Oncology Research)
Source: Pathology Oncology Research - April 5, 2024 Category: Pathology Authors: Peter Batar Hussain Alizadeh Gyorgy Rokszin Zsolt Abonyi-Toth Judit Demeter Source Type: research
Ponatinib and STAT5 Inhibitor Pimozide Combined Synergistic Treatment Applications Potentially Overcome Drug Resistance via Regulating the Cytokine Expressional Network in Chronic Myeloid Leukemia Cells
J Interferon Cytokine Res. 2024 Apr;44(4):178-189. doi: 10.1089/jir.2023.0170.ABSTRACTChronic myeloid leukemia (CML) is a clonal myeloproliferative hematological disease characterized by the chimeric breakpoint-cluster region/Abelson kinase1 (BCR::ABL1) oncoprotein; playing a pivotal role in CML molecular pathology, diagnosis, treatment, and possible resistance arising from the success and tolerance of tyrosine kinase inhibitor (TKI)-based therapy. The transcription factor STAT5 constitutive signaling, which is influenced by the cytokine signaling network, triggers BCR::ABL1-based CML pathogenesis and is also relevant to a...
Source: Cell Research - April 5, 2024 Category: Cytology Authors: Burcin Tezcanli Kaymaz Nurcan Gumus Besne Celik İlayda Alcitepe Cigir Biray Avci Cagdas Aktan Source Type: research
Codelivery of ivermectin and methyl dihydrojasmonate in nanostructured lipid carrier for synergistic antileukemia therapy
Int J Pharm. 2024 Apr 3:124086. doi: 10.1016/j.ijpharm.2024.124086. Online ahead of print.ABSTRACTChronic myeloid leukemia is a life-threatening blood-cancer prevalent among children and adolescents. Research for innovative therapeutics combine drug-repurposing, phytotherapeutics and nanodrug-delivery. Ivermectin (Ivn) is a potent anthelmintic, repurposed for antileukemic-activity. However, Ivn exerts off-target toxicity. Methyl-dihydrojasmonate (MJ) is a phytochemical of known antileukemic potential. Herein, we developed for the first-time Ivn/MJ-coloaded nanostructured-lipid-carrier (Ivn@MJ-NLC) for leveraging the antile...
Source: Cancer Control - April 5, 2024 Category: Cancer & Oncology Authors: Fatma S Abou-Elnour Salma E El-Habashy Marwa M Essawy Ossama Y Abdallah Source Type: research
Corrigendum: Comorbidities and outcomes of patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: a real-world, nationwide, retrospective study from Hungary
Pathol Oncol Res. 2024 Mar 21;30:1611758. doi: 10.3389/pore.2024.1611758. eCollection 2024.ABSTRACT[This corrects the article DOI: 10.3389/pore.2024.1611497.].PMID:38576767 | PMC:PMC10991778 | DOI:10.3389/pore.2024.1611758 (Source: Pathology Oncology Research)
Source: Pathology Oncology Research - April 5, 2024 Category: Pathology Authors: Peter Batar Hussain Alizadeh Gyorgy Rokszin Zsolt Abonyi-Toth Judit Demeter Source Type: research
Ponatinib and STAT5 Inhibitor Pimozide Combined Synergistic Treatment Applications Potentially Overcome Drug Resistance via Regulating the Cytokine Expressional Network in Chronic Myeloid Leukemia Cells
J Interferon Cytokine Res. 2024 Apr;44(4):178-189. doi: 10.1089/jir.2023.0170.ABSTRACTChronic myeloid leukemia (CML) is a clonal myeloproliferative hematological disease characterized by the chimeric breakpoint-cluster region/Abelson kinase1 (BCR::ABL1) oncoprotein; playing a pivotal role in CML molecular pathology, diagnosis, treatment, and possible resistance arising from the success and tolerance of tyrosine kinase inhibitor (TKI)-based therapy. The transcription factor STAT5 constitutive signaling, which is influenced by the cytokine signaling network, triggers BCR::ABL1-based CML pathogenesis and is also relevant to a...
Source: Cell Research - April 5, 2024 Category: Cytology Authors: Burcin Tezcanli Kaymaz Nurcan Gumus Besne Celik İlayda Alcitepe Cigir Biray Avci Cagdas Aktan Source Type: research
Corrigendum: Comorbidities and outcomes of patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: a real-world, nationwide, retrospective study from Hungary
Pathol Oncol Res. 2024 Mar 21;30:1611758. doi: 10.3389/pore.2024.1611758. eCollection 2024.ABSTRACT[This corrects the article DOI: 10.3389/pore.2024.1611497.].PMID:38576767 | PMC:PMC10991778 | DOI:10.3389/pore.2024.1611758 (Source: Pathology Oncology Research)
Source: Pathology Oncology Research - April 5, 2024 Category: Pathology Authors: Peter Batar Hussain Alizadeh Gyorgy Rokszin Zsolt Abonyi-Toth Judit Demeter Source Type: research
Corrigendum: Comorbidities and outcomes of patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: a real-world, nationwide, retrospective study from Hungary
Pathol Oncol Res. 2024 Mar 21;30:1611758. doi: 10.3389/pore.2024.1611758. eCollection 2024.ABSTRACT[This corrects the article DOI: 10.3389/pore.2024.1611497.].PMID:38576767 | PMC:PMC10991778 | DOI:10.3389/pore.2024.1611758 (Source: Pathology Oncology Research)
Source: Pathology Oncology Research - April 5, 2024 Category: Pathology Authors: Peter Batar Hussain Alizadeh Gyorgy Rokszin Zsolt Abonyi-Toth Judit Demeter Source Type: research
Corrigendum: Comorbidities and outcomes of patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: a real-world, nationwide, retrospective study from Hungary
Pathol Oncol Res. 2024 Mar 21;30:1611758. doi: 10.3389/pore.2024.1611758. eCollection 2024.ABSTRACT[This corrects the article DOI: 10.3389/pore.2024.1611497.].PMID:38576767 | PMC:PMC10991778 | DOI:10.3389/pore.2024.1611758 (Source: Pathology Oncology Research)
Source: Pathology Oncology Research - April 5, 2024 Category: Pathology Authors: Peter Batar Hussain Alizadeh Gyorgy Rokszin Zsolt Abonyi-Toth Judit Demeter Source Type: research
Corrigendum: Comorbidities and outcomes of patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: a real-world, nationwide, retrospective study from Hungary
Pathol Oncol Res. 2024 Mar 21;30:1611758. doi: 10.3389/pore.2024.1611758. eCollection 2024.ABSTRACT[This corrects the article DOI: 10.3389/pore.2024.1611497.].PMID:38576767 | PMC:PMC10991778 | DOI:10.3389/pore.2024.1611758 (Source: Pathology Oncology Research)
Source: Pathology Oncology Research - April 5, 2024 Category: Pathology Authors: Peter Batar Hussain Alizadeh Gyorgy Rokszin Zsolt Abonyi-Toth Judit Demeter Source Type: research
